Misolfa (Dienogest, Ethinylestradiol)

Dienogest/Ethinylestradiol, the active ingredients in Misolfa, are a combined estrogen‑progestogen oral contraceptive presented as a tablet for oral use. It treats prevention of pregnancy and helps regulate menstrual cycles in women of reproductive age.

GNH USA supplies Misolfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is sourced from the European Union market and meets stringent quality and regulatory standards, ensuring reliable access for healthcare providers across multiple regions. GNH USA’s distribution network enables timely delivery and compliance with local import requirements.

Misolfa, a combined estrogen‑progestogen oral contraceptive, is indicated for conditions related to reproductive hormone regulation.

- Prevention of pregnancy: Provides reliable contraceptive protection by suppressing ovulation and altering cervical mucus. - Regulation of menstrual cycles: Helps achieve more predictable bleeding patterns and reduces menstrual discomfort. - Management of hormone‑related menstrual disorders: Used to stabilize cycle length and flow in women with irregular periods.

Like other combined oral contraceptives, Misolfa may be associated with a range of adverse reactions.

Common Side Effects: - Nausea - Headache - Breast tenderness - Spotting or irregular bleeding

Serious or Rare Side Effects: - Venous thromboembolism (deep‑vein thrombosis or pulmonary embolism) - Stroke or transient ischemic attack - Severe hypertension

Before prescribing Misolfa, clinicians should consider several precautionary measures to ensure patient safety.

- Contraindications: Do not use in women with a history of thromboembolic disorders, estrogen‑dependent tumors, or uncontrolled hypertension. - Smoking: Avoid if over 35 years and a smoker, as cardiovascular risk increases. - Medication review: Assess concurrent use of enzyme‑inducing drugs that may reduce efficacy. - Pregnancy: Discontinue if pregnancy is confirmed; the product is not intended for use during pregnancy. - Breastfeeding: Use only if benefits outweigh potential risks, after consulting a healthcare professional. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Misolfa can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Enzyme inducers such as rifampicin, carbamazepine, or phenytoin may markedly reduce contraceptive effectiveness. - Certain SSRIs (e.g., fluoxetine) can increase estrogen levels, raising the risk of hepatic side effects. - Anticoagulants like warfarin may have altered effect due to estrogen‑induced changes in clotting factors.

Moderate Interactions (Monitor Closely): - Antifungals such as ketoconazole can raise plasma concentrations of ethinylestradiol. - Some antibiotics (e.g., tetracycline) may slightly diminish contraceptive efficacy. - Herbal supplements containing St. John’s wort may lower hormone levels, reducing protection.